Physician profile
Saoud Loutfi
NPI 1598750101
$993.15
in general payments reported to CMS, 2019-2025
23 companies · $348 in 2025
The $348 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.66 · 2020: $19.99 · 2021: $64.87 · 2022: $124 · 2023: $137 · 2024: $273 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $592 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $592.32 |
| Education | $165.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $115.55 | 2021-2025 | Trodelvy |
| Pfizer INC. | $106.48 | 2019-2025 | |
| Amgen INC. | $99.28 | 2022-2025 | Nplate, Vectibix, Xgeva |
| Novartis Pharmaceuticals Corporation | $93.24 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $71.58 | 2021-2024 | Calquence |
| Merck Sharp & Dohme LLC | $65.07 | 2021-2024 | Keytruda, Lynparza |
| Daiichi Sankyo INC. | $57.32 | 2024-2025 | Enhertu |
| Eisai INC. | $37.67 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $30.63 | 2024 | Libtayo |
| Jazz Pharmaceuticals INC. | $29.08 | 2025 | |
| Glaxosmithkline, LLC. | $28.93 | 2022-2025 | Bexsero, Rotarix, Pediarix |
| Takeda Pharmaceuticals U.S.A., INC. | $26.38 | 2023 | Ninlaro |
| E.R. Squibb & Sons, L.L.C. | $25.86 | 2022 | |
| Lilly USA, LLC | $25.82 | 2024 | Verzenio |
| Sumitomo Pharma America, INC. | $25.63 | 2023 | Orgovyx |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Morphosys, US INC. | $24.79 | 2023 | Monjuvi |
| Seagen INC. | $22.73 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $21.27 | 2022 | |
| Coherus Oncology, INC. | $19.99 | 2020 | |
| Genzyme Corporation | $19.37 | 2025 | |
| Incyte Corporation | $17.00 | 2021 | |
| Celgene Corporation | $16.21 | 2025 | Breyanzi |
| Mirati Therapeutics, INC. | $13.27 | 2024 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saoud Loutfi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.